Leveraging large-scale real-world data, the collaboration aims to accelerate clinical research, enhance trial efficiency, and advance data-driven innovation in life sciences and digital health.
Written by: Dillikumari. A, BPharm
Reviewed by: Pharmacally Editorial Team
Regeneron Pharmaceuticals, Inc. has entered a strategic collaboration with TriNetX to strengthen its drug discovery and development capabilities and support the creation of future digital health solutions. The agreement provides Regeneron with exclusive access to integrate large-scale genomic and proteomic datasets with TriNetX’s global phenotypic data network, which includes approximately 300 million de-identified patient records.
Under the terms of the collaboration, TriNetX will grant Regeneron secure, licensed access to its current and future health datasets, sourced from a global network of healthcare partners. Around 170 million of these patient records originate from the United States. The data is de-identified and anonymized, and any integration with Regeneron’s datasets will follow applicable data protection regulations, including HIPAA and GDPR.
The partnership will enable Regeneron to expand its Electronic Health Record (EHR)-linked genomic and proteomic database, developed through the Regeneron Genetics Center. This platform combines molecular data with longitudinal clinical records and has been built through collaborations with more than 150 healthcare and life sciences organizations globally.
By linking TriNetX’s phenotypic data with genomic and proteomic information generated by the Regeneron Genetics Center, the companies aim to enhance large-scale data analysis and improve the identification of disease targets. The integrated dataset is also expected to support artificial intelligence (AI) model development for applications in drug discovery and digital health.
As part of the agreement, Regeneron will invest up to $200 million in TriNetX, reflecting the scale and strategic importance of the collaboration.
In a statement, TriNetX Executive Chairman Jeff Margolis said the collaboration will leverage the company’s research-ready data infrastructure to advance human health through data-driven technologies. He emphasized the breadth and depth of TriNetX’s federated global network, which includes academic medical centers and research institutions.
Aris Baras, Senior Vice President and Head of the Regeneron Genetics Center, described the agreement as a major step toward building one of the most comprehensive human health databases. He noted that combining large-scale molecular data with real-world clinical information could accelerate drug development and enable predictive and preventive healthcare solutions.
Andrew Deubler, Senior Vice President and Chief Business and Administrative Officer at the Regeneron Genetics Center, highlighted the role of strategic investments in advancing technology-driven innovation. He added that the collaboration represents one of Regeneron’s most significant partnerships to date and aligns with its broader strategy to expand its network of research collaborators.
TriNetX operates a global data platform sourced from over 11,000 healthcare provider sites, enabling researchers to access and analyze real-world clinical data for a range of applications, including clinical trial design, observational research, and healthcare analytics.
References
Dilli Kumari is a Pharmacy graduate based in Ariyur, Puducherry. She has a strong interest in pharmacovigilance and is particularly drawn to data analysis within the healthcare field. She is known for her willingness to learn and continuously improve, with a keen attention to detail that sometimes leads her to spend extra time refining her work.